Clinical Trials Browser

NCT06058377 2026-04-16

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Phase 3 Recruiting

3,680 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT03606967 2026-04-02

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

625 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06954480 2025-11-19

DIAMOND

Phase 2 Recruiting

140 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05795101 2025-09-19

TRUDI

Phase 2 Recruiting

63 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

119 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06508216 2024-07-22

COMPASS-TNBC

Phase 1/2 Recruiting

50 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05215106 2024-07-08

POP-DURVA

Phase 2 Recruiting

200 enrolled

Breast

Cerebral Palsy, Triple Negative Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms